Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products. The addition of PGDx and its technology complements and accelerates Labcorp's existing liquid biopsy capabilities and expands Labcorp's leading oncology portfolio of next-generation seq

Labcorp Strengthens Oncology Leadership Position With the Addition of Personal Genome Diagnostics, a Provider of Comprehensive Liquid Biopsy and Tissue-Based Genomic Products and Services

QuidelOrtho Corp

Our indicative theme on Covid-19 Testing Stocks – which includes companies that produce or carry out tests for Covid-19 infections - is up by 24% year-to-date, roughly in line with the S&P 500. While we were somewhat cautious about the long-term prospects for Covid-19 testing stocks in 2020.

Labcorp, Quidel: Omicron Brings Covid Testing Stocks Back In Focus

LabCorp (LH) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

LabCorp (LH) Upgraded to Strong Buy: What Does It Mean for the Stock?

Laboratory Corp. of America Holdings LH, +1.40% said Tuesday it has entered an accelerated share buyback agreement with Goldman Sachs and Barclays for the repurchase of about $1 billion of its own stock. The company announced the move in a regulatory filing.

Laboratory Corp. to buy back $1 billion of stock in accelerated deal with Goldman, Barclays

Here is how LabCorp (LH) and Maravai LifeSciences Holdings, Inc. (MRVI) have performed compared to their sector so far this year.

Is LabCorp (LH) Outperforming Other Medical Stocks This Year?

Fortis

Orange

When looking for bargains, investors may want to consider the following three companies, as their stocks have low price-to-median-price-sales values when compared to the average of the S&P 500 (which stands at around 1.71 as of the writing of this article).

3 Low Price-to-Median-Price-Sales Value Stocks

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH) (the Company), a leading global life sciences company, today announced actions that its Board of Directors (the Board) and management team have taken to enhance shareholder returns. This includes: Initiating a dividend in the second quarter of 2022. The Board is targeting a dividend payout ratio of between 15-20% of adjusted earnings; Authorizing a $2.5 billion share repurchase program. As part of this program, $1 billion will be repurchased

Labcorp Announces Initiatives to Enhance Shareholder Value

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of Toxikon Corporation, a contract research organization delivering best-in-class nonclinical testing services. The addition of Toxikon to Labcorp Drug Development bolsters Labcorp's strong nonclinical development portfolio, and creates a strategic footprint for the company to partner with pharmaceutical and biotechnology clients in the Boston, Mass.,

Labcorp Completes Acquisition of Toxikon Corporation

BURLINGTON, N.C. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, and ConcertAI, LLC (ConcertAI), a leader in enterprise artificial intelligence (AI) and real-world data (RWD) solutions for life science companies and health care providers, today announced a collaboration to optimize precision oncology research. The companies will work together to launch clinical studies in ways that minimize the burden on physician practices, drive faster patient

Labcorp and ConcertAI Optimize Precision Oncology Research With Real-World Data and Artificial Intelligence

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a global life sciences company, is now offering observed self-collection for COVID-19 PCR testing in more than 500 of its patient service centers (PSCs) nationwide for people without symptoms or known exposure. By mid-December, the company plans to further expand the COVID-19 PCR test collection service to over 1,000 locations. At the PSC, the individual will use a short nasal swab to self-collect the sample in the presence of a phlebotomis

Labcorp Now Offers Observed Collection for COVID-19 PCR Testing in Over 500 Locations Nationwide, With Plans to Expand to More Than 1,000 Locations

Has LabCorp (LH) Outpaced Other Medical Stocks This Year?

McKesson

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing These Medical Stocks Right Now?

LabCorp's (LH) acquisition of Toxikon can expand its full-service drug development and medical device solutions portfolio.

LabCorp (LH) to Expand Nonclinical Development With New Buyout

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Toxikon, a contract research organization delivering best-in-class nonclinical testing services. Once completed, the transaction will create a strategic footprint for Labcorp to partner with pharmaceutical and biotechnology clients in the Boston, Mass., area and bolster its strong nonclinical development portfolio. “Adding Toxi

Labcorp to Acquire Toxikon, Expanding Nonclinical Development Testing Capabilities for Pharmaceutical, Biotech and Medical Device Clients

Syneos Health

Laboratory Corp of America Holdings (NYSE: LH) is in talks to combine some of its assets with Syneos Health Inc (NASDAQ: SYNH), reports Bloomberg citing people with knowledge of the matter.  The companies are discussing a deal in which part of LabCorp's Covance clinical research division would merge with Syneos.

Labcorp In Talks To Merge Some Covance Assets With Syneos: Bloomberg

Is LabCorp (LH) a Great Value Stock Right Now?

BURLINGTON, N.C. & NEW YORK--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, and the National Kidney Foundation (NKF), the largest patient organization dedicated to the prevention and treatment of kidney disease, announced their collaboration to promote the NKF Patient Network, the first national registry for chronic kidney disease (CKD) patients in the U.S. The NKF Patient Network will offer greater data and insights to physicians, as well as improved clinical tria

Labcorp and National Kidney Foundation Promote Patient Registry to Enhance Clinical Trial Accessibility, Diversity

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of its executive management team will participate in a virtual fireside chat at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, Nov. 9 at 1:00 p.m. ET. A live webcast of the presentation will be available via the Investor Relations section of the company's website at www.Labcorp.com and archived for replay. About Labcorp Labcorp is a leading global life sci

Labcorp to Speak at Credit Suisse 30th Annual Healthcare Conference

LabCorp (LH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Will LabCorp (LH) Gain on Rising Earnings Estimates?

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that Marcia Eisenberg, Ph.D., chief scientific officer of Labcorp Diagnostics, was recognized by Fierce Healthcare as one of its “2021 Women of Influence.” The award honors leaders who are defining the future of health care, have tangibly influenced the industry during the prior year and have a history of guiding others in their careers. “Over the past three decades, I've worked alongs

Dr. Marcia Eisenberg, Labcorp Diagnostics Chief Scientific Officer, Named to Fierce Healthcare's 2021 Women of Influence

Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q3 2021 Results - Earnings Call Transcript

LabCorp's (LH) Q3 Diagnostics revenues get significantly impacted by drop in sales for COVID-19 testing.

LabCorp (LH) Q3 Earnings Surpass Estimates, 2021 View Up

LabCorp (LH) delivered earnings and revenue surprises of 42.98% and 13.53%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) Q3 Earnings and Revenues Beat Estimates

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading life sciences company, today announced results for the third quarter ended September 30, 2021, and raised full-year guidance. “Labcorp delivered another quarter of strong performance as we continue to leverage innovation, science and technology to accelerate our strategy,” said Adam Schechter, chairman and CEO of Labcorp. "Our Base Business continued to perform well and grew 14.6%. As a result of our third-quarter performance and

Labcorp Announces 2021 Third Quarter Results

LabCorp (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

News for Labcorp Holdings Inc Stock (LH)